{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:00:13Z","timestamp":1781154013005,"version":"3.54.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.1856798","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:38:02Z","timestamp":1781152682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats\u2014a critical reappraisal"],"prefix":"10.3389","volume":"16","author":[{"given":"Qinghua","family":"Ke","sequence":"first","affiliation":[{"name":"Department of Chemoradiotherapy, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Chemoradiotherapy, The First People\u2019s Hospital of Jingzhou","place":["Jingzhou, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia","volume":"394","author":"Chiesa","year":"2026","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell Malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1856798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:38:13Z","timestamp":1781152693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1856798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1856798"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1856798","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1856798"}}